NEUPOGEN APPROVED FOR BMT IN USA
Amgen's Neupogen (filgrastim) has been cleared by the US Food and Drug Administration for use in bone marrow transplantation patients. According to the firm, while it is only the second colony stimulating factor to be approved for patients in BMT (the other is Immunex' Leukine (sargramostin), it is the only CSF which works specifically on neutrophil production stimulation.
In two trials, the use of the product significantly decreased the median number of days patients had severe neutropenia following bone marrow transplantation, said the company. Side effects experienced by patients during the trials, such as vomiting and nausea, were not different than typical effects after chemotherapy and bone marrow transplantation, said the firm.
In order to assist patients unable to afford the product, Amgen has instituted a financial aid package which allows such people to qualify for free or discounted Neupogen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze